FR05C0022I2 - - Google Patents

Info

Publication number
FR05C0022I2
FR05C0022I2 FR05C0022C FR05C0022C FR05C0022I2 FR 05C0022 I2 FR05C0022 I2 FR 05C0022I2 FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 C FR05C0022 C FR 05C0022C FR 05C0022 I2 FR05C0022 I2 FR 05C0022I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR05C0022C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0022(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of FR05C0022I1 publication Critical patent/FR05C0022I1/fr
Application granted granted Critical
Publication of FR05C0022I2 publication Critical patent/FR05C0022I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
FR05C0022C 1995-03-30 2005-05-09 Active FR05C0022I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (2)

Publication Number Publication Date
FR05C0022I1 FR05C0022I1 (en) 2005-06-10
FR05C0022I2 true FR05C0022I2 (en) 2005-10-21

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0022C Active FR05C0022I2 (en) 1995-03-30 2005-05-09

Country Status (36)

Country Link
US (1) US6417191B1 (en)
EP (1) EP0817637B1 (en)
JP (1) JP2954357B2 (en)
KR (1) KR100542536B1 (en)
CN (1) CN1103593C (en)
AP (1) AP652A (en)
AT (1) ATE220551T1 (en)
AU (1) AU715213B2 (en)
BR (3) BRPI9612992B1 (en)
CA (1) CA2216634C (en)
CZ (1) CZ295940B6 (en)
DE (3) DE122005000029I2 (en)
DK (1) DK0817637T3 (en)
EA (1) EA000626B3 (en)
EE (1) EE04047B1 (en)
ES (1) ES2179193T3 (en)
FR (1) FR05C0022I2 (en)
GE (1) GEP20022647B (en)
HK (1) HK1009401A1 (en)
HU (1) HU224010B1 (en)
IL (1) IL117727A (en)
LU (1) LU91171I2 (en)
MX (1) MX9707316A (en)
MY (1) MY115461A (en)
NL (1) NL300195I2 (en)
NO (2) NO313787B1 (en)
NZ (1) NZ306419A (en)
OA (1) OA10616A (en)
PL (1) PL187085B1 (en)
PT (1) PT817637E (en)
RO (1) RO117995B1 (en)
SI (1) SI0817637T1 (en)
SK (1) SK283825B6 (en)
TR (1) TR199701074T1 (en)
UA (1) UA60293C2 (en)
WO (1) WO1996030025A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333099A (en) * 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
EP0979082A1 (en) * 1997-05-17 2000-02-16 Glaxo Group Limited Antiviral combinations containing the carbocyclic nucleoside 1592u89
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (en) * 2002-06-04 2005-03-23 Glaxo Group Ltd PHARMACEUTICAL COMPOSITIONS
PT1583542E (en) 2003-01-14 2008-09-17 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
KR20050119652A (en) 2003-03-24 2005-12-21 에프. 호프만-라 로슈 아게 Benzyl-pyridazinons as reverse transcriptase inhibitors
DE602004030369D1 (en) 2003-10-24 2011-01-13 Immunaid Pty Ltd THERAPY PROCESS
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
JP2009515826A (en) 2005-10-19 2009-04-16 エフ.ホフマン−ラ ロシュ アーゲー Phenyl-acetamide NNRT inhibitor
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
PL2120878T3 (en) * 2007-02-09 2015-01-30 Alphapharm Pty Ltd A dosage form containing two active pharmaceutical ingredients in different physical forms
HUE026456T2 (en) 2009-05-27 2016-05-30 Biotempus Ltd Methods of treating diseases
RS57323B1 (en) 2010-01-27 2018-08-31 Viiv Healthcare Co Antiviral therapy
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
TW201622731A (en) 2014-04-08 2016-07-01 泰瓦藥品工業有限公司 Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising darunavir and ritonavir
CN112430250A (en) 2014-08-12 2021-03-02 莫纳什大学 Lymphatic prodrugs
CN114031658A (en) 2015-09-08 2022-02-11 莫纳什大学 Lymphatic prodrugs
AU2018324037A1 (en) * 2017-08-29 2020-04-16 Monash University Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
EP0639971B1 (en) * 1992-05-13 1999-09-22 The Wellcome Foundation Limited Therapeutic combinations
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
ATE230267T1 (en) 1996-06-25 2003-01-15 Glaxo Group Ltd COMPOSITIONS CONTAINING VX478, ZIDOVUDINE AND 159U89 FOR USE IN THE TREATMENT OF HIV
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
DE10226522A1 (en) * 2002-06-14 2003-12-24 Degussa Use of transition metal complexes with nitrogen-containing multidentate ligands as a bleaching catalyst and bleaching agent composition

Also Published As

Publication number Publication date
SK129597A3 (en) 1998-07-08
DE122005000029I1 (en) 2005-10-06
HU224010B1 (en) 2005-04-28
NO313787B1 (en) 2002-12-02
BR9607851A (en) 1998-07-21
DE69622386D1 (en) 2002-08-22
ATE220551T1 (en) 2002-08-15
WO1996030025A1 (en) 1996-10-03
UA60293C2 (en) 2003-10-15
DE122005000029I2 (en) 2006-04-27
CZ309097A3 (en) 1998-05-13
PL322532A1 (en) 1998-02-02
DE69622386T2 (en) 2003-02-13
JPH10511682A (en) 1998-11-10
DK0817637T3 (en) 2002-11-11
AP9701089A0 (en) 1997-10-31
ES2179193T3 (en) 2003-01-16
NO2005014I1 (en) 2005-06-06
AP652A (en) 1998-06-19
SI0817637T1 (en) 2002-10-31
SK283825B6 (en) 2004-02-03
LU91171I2 (en) 2005-07-04
IL117727A (en) 1999-11-30
PL187085B1 (en) 2004-05-31
JP2954357B2 (en) 1999-09-27
EE9700240A (en) 1998-04-15
HK1009401A1 (en) 1999-09-10
AU715213B2 (en) 2000-01-20
EP0817637B1 (en) 2002-07-17
BRPI9607851B8 (en) 2019-11-05
NZ306419A (en) 2000-01-28
PT817637E (en) 2002-11-29
OA10616A (en) 2001-03-15
HUP9801571A3 (en) 2001-04-28
LU91171I9 (en) 2018-12-28
NO2005014I2 (en) 2008-02-11
MX9707316A (en) 1997-11-29
KR100542536B1 (en) 2006-03-23
MY115461A (en) 2003-06-30
FR05C0022I1 (en) 2005-06-10
EA000626B3 (en) 2016-04-29
IL117727A0 (en) 1996-07-23
EP0817637A1 (en) 1998-01-14
EA000626B1 (en) 1999-12-29
BRPI9612992B1 (en) 2020-08-04
GEP20022647B (en) 2002-03-25
CN1185110A (en) 1998-06-17
RO117995B1 (en) 2002-12-30
EE04047B1 (en) 2003-06-16
KR19980703420A (en) 1998-11-05
NL300195I1 (en) 2005-08-01
TR199701074T1 (en) 1998-02-21
CN1103593C (en) 2003-03-26
EA199700203A1 (en) 1998-02-26
NO974510D0 (en) 1997-09-29
NL300195I2 (en) 2005-11-01
BR9607851B1 (en) 2009-01-13
CA2216634C (en) 2004-07-20
HUP9801571A2 (en) 1999-01-28
CA2216634A1 (en) 1996-10-03
AU5497296A (en) 1996-10-16
CZ295940B6 (en) 2005-12-14
US6417191B1 (en) 2002-07-09
NO974510L (en) 1997-09-29

Similar Documents

Publication Publication Date Title
DE69638352D1 (en)
DE69637714D1 (en)
LU91171I9 (en)
DK143195A (en)
ECSDI950232S (en)
FR2729268B1 (en)
DK0727898T3 (en)
FR2730000B1 (en)
FR2729686B1 (en)
IN184955B (en)
ECSDI950233S (en)
IN183362B (en)
DK126096A (en)
IN185793B (en)
IN187218B (en)
IN188139B (en)
ECSDI950231S (en)
ECSDI950230S (en)
ECSDI950229S (en)
ECSDI950223S (en)
EP0763823A4 (en)
CN3035868S (en)
EP0730889A3 (en)
EP0742395A3 (en)
CN3032390S (en)